Hemogenyx Pharmaceuticals PLC Align Research Initiation of Coverage
2018年3月1日 - 4:02PM
RNSニュース (英語)
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
01 March 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Align Research Initiation of Coverage
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, announces that Align Research ("Align")has today
initiated research coverage on the Company. The Company is pleased
to note the comments of Align in their research note ("Note")
including its "conviction buy" stance and target price of 18.15
pence. However, the Board wishes to emphasize that the views
expressed in the Note are those of Align alone.
The Note should be read in full. To download it visit:
http://www.alignresearch.co.uk/cpt-company/hemogenyx-pharmaceuticals/
or www.hemogenyx.com/research/
As always shareholders should speak to their own financial
adviser before entering into any dealings in the Company's shares.
In particular, whilst the Company confirms the views attributed to
it in the Note on recent trading, there is no certainty that the
possible future collaborations and the Board's great confidence can
be realized in full or within the Company's current development
timetable. The views expressed by Align on the Company's valuation
and prospects are a matter of opinion and the Company is in no
position to comment on whether they are accurate.
The Company also wishes to draw attention to the key risks
identified by Align and its disclaimer and risk warning and the
qualifications that it makes in its conclusion to the Note.
Shareholders should also note that the Company is a research client
of Align and that Align holds shares in the Company
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Via Walbrook PR
Officer & Co-Founder
Dr Robin Campbell, Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469 0930
Lucy Williams/Duncan Vasey
Walbrook PR (UK Media & Investor Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Relations)
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or lowell@lowellgoodman.net
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, HemoGenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York.
HemoGenyx is a preclinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of
novel therapies and treatments for blood diseases such as leukemia
and lymphoma. The company's leading technologies aim to change the
way in which bone marrow/hematopoietic stem cell (BM/HSC)
transplants are performed and improve their efficacy. HemoGenyx's
two distinct and complementary products include an immunotherapy
product for patient conditioning-the CDX bi-specific antibody-and a
cell therapy product for BM/HSC transplantation-the HuPHEC. Each of
these products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care.
For more information, visit www.hemogenyx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGMGZZGRGGRZZ
(END) Dow Jones Newswires
March 01, 2018 02:02 ET (07:02 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 9 2024 まで 10 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
過去 株価チャート
から 10 2023 まで 10 2024